Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Inhibikase Therapeutics (IKT) Long-Term Debt Issuances (2020)

Inhibikase Therapeutics (IKT) has 1 years of Long-Term Debt Issuances data on record, last reported at $27550.0 in Q2 2020.

On a quarterly basis, Long-Term Debt Issuances changed N/A to $27550.0 in Q2 2020 year-over-year; TTM through Dec 2021 was $27550.0, a 89.9% decrease, with the full-year FY2020 number at $272800.0, changed N/A from a year prior.
Long-Term Debt Issuances reached $27550.0 in Q2 2020 per IKT's latest filing, down from $245250.0 in the prior quarter.
Over the last five years, Long-Term Debt Issuances for IKT hit a ceiling of $245250.0 in Q1 2020 and a floor of $27550.0 in Q2 2020.